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Background: Biomarkers are needed to predict clinical outcomes for microfracture and osteotomy surgeries to ensure patients
can be better stratified to receive the most appropriate treatment.
Purpose: To identify novel biomarker candidates and to investigate the potential of a panel of protein biomarkers for the predic-
tion of clinical outcome after treatment with microfracture or osteotomy.
Study Design: Descriptive laboratory study.
Methods: To identify novel candidate biomarker proteins, we used label-free quantitation after liquid chromatography–tandem
mass spectrometry of dynamic range-compressed synovial fluids (SFs) from individuals who responded excellently or poorly
(based on change in Lysholm score) to microfracture (n = 6) or osteotomy (n = 7). Biomarkers that were identified in this proteomic
analysis or that relate to osteoarthritis (OA) severity or have predictive value in another early OA therapy (autologous cell implan-
tation) were measured in the SF of 19 and 13 patients before microfracture or osteotomy, respectively, using commercial immu-
noassays, and were normalized to urea. These were aggrecanase-1 (ADAMTS-4), cartilage oligomeric matrix protein (COMP),
hyaluronan (HA), lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1), matrix metalloproteinase 1 and 3, soluble
CD14, S100 calcium binding protein A13, and 14-3-3 protein theta (YWHAQ). Levels of COMP and HA were also measured in
the plasma of these patients. To find predictors of postoperative function, multivariable regression analyses were performed.
Results: Proteomic analyses highlighted YWHAQ and LYVE-1 as being differentially abundant between the clinical responders/
improvers and nonresponders after microfracture. A linear regression model after backward variable selection could relate pre-
operative concentrations of SF proteins (HA, YWHAQ, LYVE-1), activity of ADAMTS-4, and patient demographic characteristics
(smoker status and sex) with Lysholm score 12 months after microfracture. Further, a generalized linear model with elastic net
penalization indicated that lower preoperative activity of ADAMTS-4 in SF, being a nonsmoker, and being younger at the time
of operation were indicative of a higher postoperative Lysholm score (improved joint function) after osteotomy surgery.
Conclusion: We have identified biomarkers and generated regression models with the potential to predict clinical outcome in
patients treated with microfracture or osteotomy of the knee.
Clinical Relevance: Candidate protein biomarkers identified in this study have the potential to help determine which patients will
be best suited to treatment with microfracture or osteotomy.
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assays; enzyme activity assays
Some of the most widely used surgical approaches that aim
to repair chondral or osteochondral defects of the knee
include microfracture and osteotomy.10,41 Although
advanced cell therapy approaches such as autologous chon-
drocyte implantation (ACI) have been highlighted as more
efficacious and cost-effective for repair of chondral and
osteochondral defects of the knee,26 these surgeries are
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not available in nonspecialist orthopaedic centers and
require access to Good Manufacturing Practice (GMP) facil-
ities able to culture expand patients’ cells; hence, alterna-
tive surgeries such as microfracture and osteotomy are
often used. Microfracture and osteotomy can be economical
treatments, but only for those individuals in whom these
surgeries are successful; therefore, there is a need for early
identification of patients who are likely to benefit from
microfracture and osteotomy. The Osteoarthritis Research
Society International (OARSI) previously highlighted the
need to identify biomarkers that can predict which patients
are most likely to benefit from surgical interventions to
delay or prevent the development of osteoarthritis (OA),16
and we are unaware of any published studies that have
addressed this need for microfracture or osteotomy.
Work to identify biomarkers (biochemical and imaging)
for the diagnosis and prognosis of OA has been abundant
and ongoing for many years.13 However, far fewer studies
have focused on the identification of biomarkers to predict
clinical outcome in response to a surgical intervention to
prevent or delay the onset of OA. To our knowledge, the
only published studies that have used human samples
with this aim have been related to ACI11,12,45 or anterior
cruciate ligament (ACL) reconstruction.18 Wright et al45
demonstrated that assessment of proteins of known biolog-
ical relevance to OA within the synovial fluid (SF) can
identify protein markers that, when combined with known
demographic or surgical risk factors, can be used to predict
the success of surgical treatment with ACI. In support for
this approach, Latterman et al18 demonstrated that assess-
ment of OA-related proteins, as well as inflammatory cyto-
kines, in SF collected at the time of surgery could be used
to differentiate between individuals who clinically
improved and those who did not at 2 years after ACL
reconstruction. As alternatives to assessing OA-related
proteins, unbiased discovery-based approaches have been
used to identify within-treatment proteome shifts that
are unique to ACI nonresponders.11,12 In the study
described here, we used both these targeted and nontar-
geted approaches. We hypothesized that these approaches
can be used to identify protein biomarkers that may pre-
dict an individual’s probability of a successful outcome in
response to microfracture or osteotomy.
Proteins were selected for our targeted analysis that
have known biological relevance to cartilage degeneration/
turnover and OA, along with proteins that have previously
been highlighted as candidate biomarkers for the prediction
of outcome to ACI via nontargeted proteomic analyses.11,12
The cartilage matrix–related proteins and enzymes
assessed in this study were cartilage oligomeric matrix pro-
tein (COMP), hyaluronan (HA), A disintegrin and metallo-
proteinase with thrombospondin motifs 4 (ADAMTS-4;
aggrecanase-1), and matrix metalloproteinases 1 and 3
(MMP-1 and MMP-3). COMP is a noncollagenous glycopro-
tein involved in collagen-collagen interactions.43 HA is a gly-
cosaminoglycan that constitutes a key component of the
cartilage extracellular matrix.37 Both COMP and HA have
long been suggested as prognostic biomarkers of OA pro-
gression.37,38 ADAMTS-4, MMP-1, and MMP-3 are key
enzymes in regulating cartilage homeostasis. ADAMTS-4
cleaves large chondroitin sulphate HA-binding proteogly-
cans including aggrecan.34 MMPs also break down other
key cartilage matrix components, specifically collagen II
by MMP-1 and a broad range of matrix components includ-
ing aggrecan by MMP-3.24,25 Soluble CD14 (sCD14) was
assessed, as this protein has been associated with OA pro-
gression and pain.8 CD14 is found on the surface of mono-
cytes and macrophages and regulates the production of
a number of inflammatory mediators.8 S100 calcium bind-
ing protein A13 (S100A13) was also assessed, as this protein
has previously been highlighted as having potential to pre-
dict ACI outcome after untargeted proteomic analysis.12
S100A13 is a member of the S100 family of proteins, which
have a wide variety of extracellular functions, many of
which act as alarmins that contribute to the regulation of
immune and inflammatory responses and posttraumatic
injury respones46; however, no specific relation between
S100A13 and the joint environment homeostasis or inflam-
matory response has been reported.
Within the field of OA, much of the work aimed at identi-
fying prognostic and predictive biomarkers has relied on SF
because this fluid represents the whole joint environment.
However, identification of protein biomarkers that can be
assessed within the blood rather than the SF remains the
ultimate goal in clinical practice, as this would provide
a less invasive method of predicting which individuals are
likely to benefit from surgical procedures to treat cartilage
defects. Therefore, we have also assessed some commonly
studied OA-related biomarker proteins within the plasma of
patients who have undergone osteotomy and microfracture.
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METHODS
Patients
After local research ethics committee approval was
granted (11/NW/0875 and 06/Q6201/9; see declarations)
and with informed consent of patients, blood and SF sam-
ples were collected from individuals undergoing osteotomy
or microfracture at our center between 2015 and 2019,
along with samples collected in our research group’s bio-
bank since 2006. Before surgery, patients’ demographic
details were recorded, and their functional status was
determined via completion of the modified Lysholm
patient-reported outcome measure.22,39 The modified
Lysholm score ranges from 0 to 100, with 100 representing
‘‘perfect’’ knee function.22 Individuals were deemed to
respond to surgery if they demonstrated a minimal clini-
cally important difference (MCID) of a 10-point increase
in Lysholm score between pre- and postoperative assess-
ments.9,33,36 Postoperative scores were collected at approx-
imately 12 months after surgery (median 6 interquartile
range, 13 6 6.5 months). The severity of a patient’s OA
before surgery was determined using Kellgren-Lawrence
grading of radiographs14 independently by 2 consultant
orthopaedic surgeons (P.G., P.J.). A mean of the 2 sur-
geons’ scores was taken as the preoperative Kellgren-
Lawrence score. The details of these patients are described
in Table 1. Samples from the whole patient cohort were
assessed for all biomarker proteins including those related
to OA and cartilage biology, and to validate those proteins
identified in this study via exploratory proteomic analysis
(Table 1).
A group of samples were selected for proteomic analysis
from a subgroup of patients who demonstrated the greatest
improvement in clinical score (responders) or the least
improvement or a worsening of function (nonresponders)
at 12 6 2 months after osteotomy or microfracture. Other
selection criteria for the proteomic study included having
.2 mL of SF sample for analysis; no blood contamination
staining of the SF, as this has been demonstrated to alter
the detection of proteins within the fluid44; and a dilution
factor of \14 (detailed in Table 2).
SF and Plasma Collection and Storage
SF was collected from patients’ knee joints immediately
before microfracture or osteotomy surgery by injecting
20 mL of saline and then extending and flexing the leg at
least 20 times before intra-articular aspiration of as
much SF as possible.32 At this time, blood samples were
also collected by venipuncture. SF and plasma were then
centrifuged at 6000g for 15 minutes at 4C, and the super-
natant was removed before being divided into aliquots and
stored in –196C liquid nitrogen before analyses.
Proteomic Analysis of SFs
Sample Preparation and Analysis Using Proteomics. SF
samples were not pooled at any point of the proteomic
TABLE 1
Demographic Characteristics and Biomarker Data for Participants Treated With Either Osteotomy or Microfracturea
Microfracture (n = 19) Osteotomy (n = 13)
Patient characteristics
Age, y 34 (22) [17-67] 46 (9) [31-58]
Male, n 12 8
Body mass index 25 (5) [19-36] 30 (2) [21-34]
Baseline Lysholm score 50 (30) [23-88] 52 (17) [17-66]
Postoperative Lysholm score 54 (35) [16-96] 79 (33) [38-92]
Baseline Kellgren-Lawrence score 0.5 (1) [0-2] 2 (1) [1-3]
Treatment side: right leg, n 9 6
Treatment side: left leg, n 10 7
Smokers, n 1 2
Synovial fluid markers
COMP, mgmL-1 157.3 (90.3) [29.1-383.2] 147.1 (129.8) [44.5-310.6]
HA, mgmL-1 17.7 (9.1) [3.1-34.0] 14.2 (23.1) [1.6-48.9]
sCD14, ngmL-1 765.6 (1516.9) [11.3-5014.7] 2308.4 (2144.2) [479.1-3880.2]
ADAMTS-4/aggrecanase-1, ngmL-1 0.4 (21.4) [0.4-44.0] 0.4 (17.4) [0.4-34]
MMP-1, ngmL-1 0.3 (5.3) [0.04-22.9] 1.7 (7.9) [0.3-10.1]
MMP-3, ngmL-1 136.2 (205.2) [0-5060.9] 532.7 (515.8) [163.8-2867.8]
S100A13, pgmL-1 2529.4 (2116.3) [946.5-6795.6] 1552.5 (2723.2) [0-5807.8]
YWHAQ, ngmL-1 0.5 (0.5) [0.5-10.6] 1.5 (2.0) [0.5-7.98]
LYVE-1, ngmL-1 4.1 (4.1) [1.5-16.1] 1.1 (1.5) [0.5-5.3]
Plasma markers
COMP, ngmL-1 491.4 (155.3) [342.4-758.2] 629.5 (230.7) [342.4-1212.0]
HA, ngmL-1 0.5 (5.0) [0.5-20.9] 0.5(16.2) [0.5-57.8]
aValues are expressed as median (interquartile range) [range] unless otherwise noted. ADAMTS-4, A disintegrin and metalloproteinase
with thrombospondin motifs 4; COMP, cartilage oligomeric matrix protein; HA, hyaluronan; LYVE-1, lymphatic vessel endothelial hyalur-
onan receptor 1; sCD14, soluble CD14; S100A13, S100 calcium binding protein A13; YWHAQ, 14-3-3 protein theta.
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sample preparation or mass spectrometry stages; therefore,
the protein abundance was quantified for each of the 13
samples, and mean protein abundance for each experimen-
tal group was calculated before the analysis of protein
changes.
SF Preparation and Protein Equalization Using Proteo-
Miner. ProteoMiner beads (BioRad) were used to compress
the dynamic range of proteins to allow improved identification
of low-abundance proteins, as described previously.12,28 The
total protein concentration of hyaluronidase (1 mgmL-1)2
treated SFs12 was quantitated using a Pierce 660-nm protein
assay (Thermo Scientific). Next, 5 mg of total protein was
incubated with ProteoMiner beads following kit instructions.
Proteins attached to the beads were then treated with
0.05% (wt/vol) RapiGest (Waters) in 25 mM ammonium bicar-
bonate for 10 minutes at 80C before reduction, alkylation,
and in situ protein digestion, which was carried out using
trypsin in LoBind protein tubes (Eppendorf) without removal
of the beads. Samples were acidified using trifluoroacetic acid
to a final concentration of 0.5% (vol/vol) and multiple centrifu-
gation steps to inactivate and precipitate the RapiGest deter-
gent. Peptide-containing supernatant fractions were then
frozen at 220C before being analyzed using liquid chroma-
tography2tandem mass spectrometry (LC-MS/MS).
LC-MS/MS and Label-Free Quantification. A Nano-
Acquity ultraperformance LC (Waters) coupled online to
a Q-Exactive Quadrupole-Orbitrap instrument (Thermo-
Fisher Scientific) was used to analyze tryptic peptides on
a 2-hour gradient.12,28 For label-free quantification, raw files
of the acquired data were analyzed (as described previ-
ously12) in ProgenesisQI software (Waters),27 and the top 5
spectra for each feature were used for peptide identification
in a locally implemented Mascot server (Version 2.3.01),
searching against the Unihuman Reviewed database. Pep-
tide matches above an identified threshold were adjusted to
give a false discovery rate of 1% before the protein identifica-
tions were reimported into ProgenesisQI for the label-free
relative quantification of unique peptides. Statistical analysis
was performed using ProgenesisQI software; in brief, trans-
formed normalized abundances were used for 1-way analysis
of variance, and all peptides (with P \ .05) of an identified
protein were included. To select proteins for biochemical val-
idation, the mean abundance of each protein in each of the
experimental groups was calculated, and significant proteins
(false discovery rate; P \ .05) with a 62.0-fold change
between comparator groups were reported.
Assessment of Protein Abundances Using
Enzyme-Linked Immunosorbent Assay (ELISA)
Assessment of Proteins Identified in the LC-MS/MS
Proteomic Analyses Using ELISA. We selected 14-3-3 pro-
tein theta (YWHAQ) to validate the LC-MS/MS findings,
as this protein was detected only in nonresponders and
was not detected at all in responders to microfracture,
deeming it an ideal candidate biomarker. Lymphatic vessel
endothelial hyaluronan receptor 1 (LYVE-1) was also
selected to validate the LC-MS/MS findings because it
can bind to HA,47 a key component of articular cartilage
and SF. LYVE-1 is also highly expressed in the synovium
of OA patients who have synovial villous hypertrophy
and chronic inflammatory cell infiltrate.47 YWHAQ and
LYVE-1 were quantified using ELISAs (YWHAQ, Cusabio;
LYVE-1, R&D Systems) according to the manufacturers’
instructions. SF samples from the same patients as were
assessed in the LC-MS/MS analysis were used to validate
the proteomic findings. These samples were assessed in
duplicate, and mean optical density values were used to
calculate the protein concentration. SF was diluted 1:50
for the assessment of LYVE-1 and was assayed neat (ie,
not further diluted above the dilution due to lavage) for
YWHAQ. The concentration of each protein was normal-
ized to total protein concentration, to validate the LC-
MS/MS, as equal concentrations of protein were loaded
onto the ProteoMiner beads. Statistical analysis was
TABLE 2
Demographic Data for Participants Whose Synovial Fluid Samples Were Used for Proteomic Analysis and Who














Difference in Lysholm score 44 (21 to 62) –8 (0 to 216) .004 36 (16 to 72) –3 (0 to 24) .070
Baseline Kellgren-Lawrence score 2 (1.5 to 2.5) 2.5 (1 to 3) .465 0 (0 to 0) 1 (1 to 2) .070
Age, y 44 (29 to 59) 40 (31 to 46) .807 25 (19 to 34) 38 (24 to 46) .201
Male, n 3 2 ..999 1 2 ..999
Body mass index 34 (30 to 35) 30 (28 to 30) .053 20 (19 to 21) 34 (29 to 38) .095
Treatment side: right, n 1 2 ..999 2 3 ..999
Treatment side: left, n 2 2 ..999 1 0 ..999
Smoker, n 0 1 ..999 1 0 .400
Dilution factor of synovial fluid 4 (0 to 9) 7 (3 to 13) .856 7 (6 to 8) 7 (6 to 10) .877
aData are shown as median (range) unless otherwise indicated. None of the demographic parameters, other than difference in Lysholm
scores, showed differences between responders (R) and nonresponders (NR) in individuals whose synovial fluids were compared for each sur-
gical procedure (Lysholm, age, body mass index, dilution factor: unpaired t test; sex, treatment side, smoker status: Mann-Whitney U test).
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performed in GraphPad Prism Version 8.0. These proteins
were then included in ‘‘targeted’’ biomarker analyses in the
larger cohort of patients (Table 1) and were included in mul-
tivariable regression modeling to determine whether they
had any predictive value over and above other proteins.
Assessment of OA- and Cartilage-Associated Proteins
Using ELISA. Targeted analyses of proteins that are asso-
ciated with the development of OA and with known carti-
lage biology were performed using ELISA. These
included proteins that we have previously highlighted as
associated with clinical outcome in patients undergoing
cell therapy via ACI for the treatment of early OA.11,12,45
Levels of COMP and HA in both the SF and the plasma
were assessed using an ELISA (BioVendor Laboratory
Medicine) and an enzyme-linked protein binding assay
(Corgenix), respectively, as described previously.45 As in
our previous work, SF concentrations of sCD14 were mea-
sured using a Quantikine ELISA kit (Biotechne), and
ADAMTS-4 (aggrecanase-1) enzyme activity assessed
using an endpoint fluorometric substrate assay (SensoLyte
520 aggrecanase-1 Assay Kit; AnaSpec).45 Concentrations
of MMP-1, MMP-3, and S100A13 were assayed using
duo-sets (MMP-1 and S100A13; Biotechne) or Quantikine
ELISAs (MMP-3; Biotechne).11,12 All assays were opti-
mized to determine the appropriate sample dilution factor
(over and above dilution due to lavage) as follows:
ADAMTS-4, undiluted; sCD14, 1:200; COMP, 1:1000; HA,
1:3000; MMP-1, 1:3; MMP-3, 1:100; and S100A13, 1:20.
Plasma samples were diluted 1:50 for COMP and assayed
neat for HA. The concentration of each protein was nor-
malized to the dilution factor of the SF. To determine the
dilution of the SF (due to lavage), urea concentrations in
the SF and plasma were assessed using a QuantiChrom
urea assay kit (Universal Biologicals), and SF biomarker
values were normalized to the urea concentration in blood
plasma as described previously.17 The principle of this
method to determine dilution factor is based on the strong
correlation between the concentration of urea in the SF
and plasma of an individual; therefore, the SF volume
can be calculated by assessing matched patient SF and
plasma samples.17 Median baseline protein biomarker lev-
els are summarized in Table 1.
Statistical Analysis
Data analyses were performed using the statistical program-
ming language R Version 4.0.2.31 Independent models were
built for both the total microfracture (n = 19) and the osteot-
omy (n = 13) cohorts. The postoperative Lysholm score was
used as the dependent variable, and independent variables
were preoperative Lysholm score, patient age at the time
of microfracture or osteotomy, body mass index, smoker sta-
tus, and baseline level of the 9 SF biomarkers (COMP, HA,
sCD14, ADAMTS-4, MMP-1, MMP-3, S100A13, LYVE-1,
and YWHAQ) and the 2 plasma biomarkers (HA and
COMP). Imputed values were used when there were nonde-
tections for any of the proteins assessed using ELISA.45 For
sCD14, plasma HA, and YWHAQ, the imputed value was
taken as equal to (1/O2) times the lowest detected value
(sCD14, 11.3; plasma HA, 0.5; YWHAQ, 0.5), which was
the value applied to ADAMTS-4 nondetections in our previ-
ous study (0.40).45 Any missing data were imputed using
multiple imputation by chained equations.1 The number of
model features compared with the number of observations
was relatively high, and therefore linear regression with
elastic net penalization was performed. Elastic net penaliza-
tion is a combination of least absolute shrinkage and selec-
tion operator (LASSO) and ridge regression. LASSO
penalization shrinks each predictor differently and allows
variables to be removed entirely by shrinking coefficients
to zero,42,50 whereas for ridge regression, the penalty term
shrinks the effect of the predictor equally and none are
reduced to zero. Thereby, elastic net can eliminate features
entirely and allows for reduction of the effect of less impor-
tant model features.
To provide confidence in the findings and to build mod-
els that best represented the different datasets, multivari-
able linear regression models were built and variables
selected using backward variable selection. Backward
elimination removes the least significant effect that does
not meet the level for remaining in the model, and this is
repeated until no other effect in the model meets the spec-
ified level for removal. This method allows one to account
for collinearity between variables.6
Protein markers that demonstrated a significant contri-
bution to the models (P \ .05) were then assessed for their
potential to predict outcome to surgery based on the
‘‘responder’’ definitions given previously, specifically an
MCID in Lysholm score of at least 10 points at 12 months
after surgery. When patients were categorized as respond-
ers and nonresponders, a small number of patients
remained in each response arm for the 2 different surger-
ies. Therefore, to assess whether there were differences
in the activity or expression of these enzymes and proteins,




From the overall cohort, 13 patients were selected for proteo-
mic analysis of the SF, based on the selection criteria detailed
in the Methods section. After osteotomy, 3 donors were con-
sidered extreme responders with a mean improvement of
44 Lysholm points (range, 21-62 points), and 4 donors were
considered nonresponders with a mean decrease in Lysholm
score of 8 points (range, 0-16 points). After microfracture, 3
donors were deemed extreme responders (mean improve-
ment of 26 Lysholm points; range, 16-72 points), and a further
3 donors were deemed extreme nonresponders (mean
decrease of 3 Lysholm points; range 0-4, points). The demo-
graphic information for these patients is shown in Table 2.
To assess candidate biomarkers in a larger cohort, this
study included 13 patients undergoing osteotomy and 19
patients undergoing microfracture (Table 1). In osteotomy
patients, the mean 6 SD baseline Lysholm score was 49.0
6 13.9 points, which improved to 72.0 6 21.0 points at 16
6 8.9 months after osteotomy surgery. In microfracture
1516 Hulme et al The American Journal of Sports Medicine
patients, the mean 6 SD baseline Lysholm score was 50.7
6 18.7 points, which improved to only 58.7 6 25.6 points at
15.2 6 9.6 months postoperatively. When patients were
defined as responders or nonresponders to surgery based
on an MCID of 10 Lysholm points, 8 individuals who
underwent osteotomy were responders, with a median
increase in Lysholm points of 37 points (range, 16 to 62
points), and 5 individuals who had osteotomy were nonres-
ponders, with a median Lysholm point change of 24 points
(range, 0 to 216 points). Further, 8 patients who had
microfracture surgery were responders, with a median
Lysholm point increase of 23 points (range, 12 to 72
points), and 11 who had microfracture surgery were non-
responders, with a median Lysholm point change of 23
points (range, 8 to 234 points). This study entailed sam-
ples from 20 male patients (8 osteotomy and 12 microfrac-
ture) and 12 female patients, aged between 17 and 67 years
at the time of surgery. Table 1 details the demographic var-
iables of these patients.
Differential Abundance of SF Proteins
in Nonresponders Compared With Responders
to Microfracture Identified Using Proteomic Analysis
Individuals who did not respond well clinically to micro-
fracture demonstrated a differential baseline proteome
compared with those who responded well. We found that
30 proteins were differentially abundant (62.0-fold; P \
.05) in the preoperative SF of responders compared with
nonresponders of microfracture (Table 3). YWHAQ was
present in the SF of only the selected individuals who did
not respond to microfracture, and no presence of this pro-
tein was detected using LC-MS/MS in the responders. Con-
versely, small ubiquitin-related modifier 4 (SUMO4) was
detected only in the SF of responders to microfracture
and not in the nonresponders. LYVE-1, a protein that
was of biological interest because it can bind to HA,47
was 6-fold higher in the selected microfracture responders
compared with nonresponders.
TABLE 3
Fold Change of Proteins That Were Differentially Abundant (62.0-fold; false discovery rate, P \ .05)
in the Preoperative Synovial Fluid of Individuals Who Did Not Improve After Microfracture (Nonresponders; n = 3)
Compared With Those Who Did Improve (Responders; n = 3)a
Protein
Description Accession Fold Change
Small ubiquitin-related modifier 4 (SUMO4) Q6EEV6 Infinity
55-kDa erythrocyte membrane protein Q00013 –2103005.6
Protein argonaute 1 Q9UL18 –147.4
Complement C1r subcomponent-like protein Q9NZP8 –11.0
Lymphatic vessel endothelial hyaluronic acid receptor 1 (LYVE-1) Q9Y5Y7 –6.0
Peroxiredoxin 4 Q13162 –4.4
Adiponectin Q15848 –2.8
IgGFc-binding protein Q9Y6R7 –2.7
Ubiquitin-conjugating enzyme E2 variant 1 Q13404 –2.5
Alpha-2–macroglobulin P01023 –2.4
Lysosomal acid phosphatase P11117 –2.1
Alpha-lactalbumin P00709 2.0
Coagulation factor XI P03951 2.1
Beta-Ala-His dipeptidase Q96KN2 2.2
Ficolin 3 O75636 2.5
Retinol-binding protein 4 P02753 2.5
Serine protease HTRA1 Q92743 2.6
28S ribosomal protein S34, mitochondrial P82930 2.9
Peptidyl-glycine alpha-amidating monooxygenase P19021 3.1
Dickkopf-related protein 3 Q9UBP4 3.1
Serum amyloid P-component P02743 3.1
Ribonuclease 4 P34096 3.3
Insulin-like growth factor II P01344 3.6
eIF-2-alpha kinase activator GCN1 Q92616 5.2
Glycosylphosphatidylinositol anchor attachment 1 protein O43292 5.4
Mannan-binding lectin serine protease 2 O00187 6.8
Poly(rC)-binding protein 3 P57721 10.7
Sodium channel protein type 8 subunit alpha Q9UQD0 11.8
Platelet factor 4 P02776 44.4
14-3-3 protein theta (YWHAQ) P27348 Infinity
aPositive numbers denote an increase in the protein in nonresponders; negative numbers denote an increase in the protein in responders.
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Differential Abundance of SF Proteins
in Nonresponders Compared With Responders
to Osteotomy Identified Using Proteomic Analysis
An SF proteome shift was found between individuals who
did or did not respond well to osteotomy. Table 4 demon-
strates the 15 proteins that were differentially abundant
(62.0-fold; P \ .05) in the SF between the 2 different clin-
ical outcome groups. Both YWHAQ and an undetectable
protein KIAA1107 demonstrated a much higher abun-
dance in the nonresponders to osteotomy compared with
the responders, with YWHAQ again being undetected in
the responders via LC-MS/MS.
Biochemical Validation of Proteomic Analyses
YWHAQ was confirmed to have undetectable concentrations
in microfracture responders and detectable concentrations
only in microfracture nonresponders when measured using
ELISA (Appendix Figure A1, available in the online version
of this article). We also assessed YWHAQ using ELISA in
the osteotomy samples used for the proteomic analyses but
found that for 2 of the responder samples, detectable levels
were measured using ELISA, whereas they were not
detected at all via LC-MS/MS (data not shown).
Further, the proteomic finding that LYVE-1 demonstrated
greater abundance in microfracture responders compared
with nonresponders could be confirmed using biochemical
analyses (mean 6 SD: responders, 154.6 6 45.0 pgmL-1/mg
protein; nonresponders, 40.4 6 14.6 pgmL-1/mg protein; P =
.01) (Appendix Figure A1, available online). These proteins
were therefore included in further studies to assess their pre-
dictive potential compared with other biomarkers and demo-
graphic data in a larger patient cohort.
Biomarker Levels
SF and plasma samples were included from all 32 patients
for analysis of targeted OA-related biomarkers and candi-
date markers identified in our nontargeted proteomic
study. The mean 6 SEM SF dilution factor was 7.8 6
7.7, with the mean dilution factor being 5.3 6 4.6 and 5.6
6 4.5 in osteotomy responders and nonresponders and
9.3 6 6.9 and 8.4 6 10.2 in microfracture responders and
nonresponders, respectively. Three of the SF proteins
(sCD14, ADAMTS-4, and YWHAQ) and HA in plasma
had samples with undetectable levels, and values were
imputed as described in the Methods section.
Multivariable Linear Models of Predictors of
Postoperative Lysholm Score After Surgical Treatment
Multivariable Linear Models for Microfracture Out-
come. Generalized linear models (GLMs) with elastic net
penalization were built using the postoperative Lysholm
score after microfracture (Appendix Table A1, available
online). For the GLM of microfracture postoperative
Lysholm score, the r2 was low (0.5) and the root mean square
error (RMSE) was high (26.4). Therefore, a linear regression
model was generated after backward variable selection; this
model better related the selected variables with the depen-
dent variable, postoperative Lysholm score (r2 = 0.71;
RMSE = 13.6) (Table 5). A number of model parameters sig-
nificantly contributed to the linear regression model for
microfracture outcomes, which were baseline levels of SF
HA, YWHAQ, plasma HA, ADAMTS-4, LYVE-1, and patient
smoker status and sex (Table 5). Although the r2 was low for
the GLM with elastic net penalization for the postmicrofrac-
ture Lysholm score (Appendix Table A1), HA was the
TABLE 4
Fold Change of Proteins That Were Differentially Abundant (62.0-fold; false discovery rate, P \ .05)
in the Preoperative Synovial Fluid of Individuals Who Did Not Improve After Osteotomy (Nonresponders; n = 4)
Compared With Those Who Did Improve (Responders; n = 3)a
Protein
Description Accession Fold Change
Integrin alpha-M P11215 –5.0
Cubilin O60494 –4.6
AT-rich interactive domain-containing protein 5B Q14865 –4.3
Filamin-A P21333 –4.1
Cystatin-C P01034 –3.9
Immunoglobulin kappa variable 3D-20 A0A0C4DH25 –2.9
Ubiquitin-conjugating enzyme E2 variant 1 Q13404 –2.8
Immunoglobulin heavy constant alpha 1 P01876 –2.7
Serum amyloid A-2 protein P0DJI9 –2.3
Immunoglobulin kappa variable 1-6 A0A0C4DH72 –2.1
Hyaluronan and proteoglycan link protein 1 P10915 2.2
Insulin-like growth factor-binding protein 5 P24593 7.3
von Willebrand factor P04275 9.7
Uncharacterized protein KIAA1107 Q9UPP5 263.0
14-3-3 protein theta (YWHAQ) P27348 Infinity
aPositive numbers denote an increase in the protein in nonresponders; negative numbers denote an increase in the protein in responders.
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variable that most strongly contributed to the model’s pre-
diction value, again highlighting this cartilage matrix pro-
tein as a predictor of clinical outcome after microfracture.
Multivariable Linear Models for Osteotomy Outcome. A
GLM with elastic net penalization was built using the post-
operative Lysholm after osteotomy (Table 6), which had
a strong correlation coefficient (r2 = 0.77) and a low
RMSE (12.1). The GLM with elastic net penalization of
postoperative Lysholm after osteotomy determined that
the variables that most strongly contributed to the model
were smoker status, age at time of operation, and preoper-
ative ADAMTS-4 activity (Table 6). These findings indicate
that being a nonsmoker and being younger at the time of
operation were related to an increased Lysholm score after
osteotomy surgery.
Assessment of Candidate Predictors in Relation to a 10-
Point Improvement in the Lysholm Score After Surgical
Treatment. The biomarker proteins that significantly con-
tributed to the predictive models of microfracture or osteot-
omy outcome were assessed to determine whether there was
a differential concentration between individuals who were
deemed responders or nonresponders to either surgery.
We found that 8 of the patients responded to microfrac-
ture surgery and 11 were nonresponders based on an
MCID of 10 Lysholm points. Figure 1 demonstrates that
the SF concentration of none of the proteins (HA, YWHAQ,
ADAMTS-4, LYVE-1) that contributed to the predictive
model of microfracture outcome was significantly different
between microfracture responders and nonresponders. The
concentration of YWHAQ was not significantly different
(P = .18; Mann-Whitney) between responders (mean 6
SEM, 0 6 0 ngmL-1) and nonresponders (2.5 6 1.3
ngmL-1) to microfracture. However, in all of the respond-
ers to microfracture surgery, YWHAQ was undetectable
(n = 8) when assessed using ELISA, but in clinical nonres-
ponders (n = 11), YWHAQ was detected in only 50% of
cases. Thus, assessment of YWHAQ in the total patient
cohort confirms the findings of the proteomic analysis
that YWHAQ is undetectable in responders to microfrac-
ture surgery. The concentration of HA within the plasma
was not significantly different between the microfracture
responders and nonresponders (P . .99).
We found that 8 of the 13 patients treated with osteot-
omy improved by at least 10 points in the Lysholm score
after 1 year and were therefore classed as responders. The
activity of ADAMTS-4 was not significantly different
between individuals who responded and did not respond
to osteotomy (Figure 2) (mean 6 SEM: responders, 0.4 6
0 ngmL-1; nonresponders, 17.9 6 7.3 ngmL-1; Mann-
Whitney; P \ .05). However, all of the individuals who
responded to osteotomy had undetectable activity of this
enzyme within their SFs, whereas activity was detectable
in 3 of the 5 nonresponders.
DISCUSSION
Identification of predictive biomarkers that are able to rec-
ognize individuals who are most likely to receive clinical
benefit from interventions aimed at delaying or preventing
the development of OA has been highlighted as a research
priority by the OARSI.16 The current study aimed to iden-
tify novel candidate biomarkers with the potential to pre-
dict outcomes of 2 of the most commonly used clinical
procedures, microfracture and osteotomy. This is the first
study, to our knowledge, to assess a panel of protein
markers for their potential to predict patient outcomes of
these surgeries. We have previously identified candidate
protein markers for the prediction of clinical outcomes of
the cell therapy ACI.45 However, the work described here
has the potential for more widespread application because
microfracture and osteotomy surgeries are offered at
a large number of hospitals, with .100,000 microfracture
TABLE 6
Generalized Linear Regression Model
With Elastic Net Penalization for Predictors of the
Postosteotomy Lysholm Score (n = 13)a
Component r2 Value RMSE Variable Importance




aFinal elastic net model parameters were alpha 0.6, lambda 5.2.
Alpha is a value between 0 and 1, where 0 is pure ridge regression,
1 is pure LASSO (least absolute shrinkage and selection operator),
and values between are a mixture of both. Lambda is the shrink-
age factor applied to model coefficients. ADAMTS-4, A disintegrin
and metalloproteinase with thrombospondin motifs 4 (ngmL-1);
RMSE, root mean square error.
TABLE 5
Linear Regression Model After Backward
Variable Selection for Predictors of the






r2 Value RMSE P Value
Total model 0.71 13.6 .04
SF HA –3.0 (0.6) .003
YWHAQ –8.09 (1.7) .003
Plasma HA –3.9 (1.1) .01
Smoker –49.9 (14.6) .01
Sex –27.3 (8.0) .02
ADAMTS-4 1.0 (0.35) .03
LYVE-1 0.001 (0.0) .04
Baseline Lysholm score –0.81 (0.3) .05
Kellgren-Lawrence score 17.5 (7.3) .05
sCD14 0.01 (0.0) .09
MMP-3 0.01 (0.0) .17
Body mass index –0.66 (0.7) .38
MMP-1 –0.71 (0.8) .41
aADAMTS-4, A disintegrin and metalloproteinase with thrombospondin
motifs 4 (ngmL-1); LYVE-1, lymphatic vessel endothelial hyaluronan recep-
tor 1 (ngmL-1); MMP-1, matrix metalloproteinase 1 (ngmL-1); MMP-3,
matrix metalloproteinase 3 (ngmL-1); plasma HA, plasma hyaluronan
(ngmL-1); RMSE, root mean square error; sCD14, soluble CD14 (ngmL-1);
SF HA, synovial fluid hyaluronan (mgmL-1); YWHAQ, 14-3-3 protein theta
(ngmL-1).
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procedures in knees, hips, or shoulders estimated to be car-
ried out per year globally.7 These procedures provide less
expensive, alternative surgical options for the treatment
of joint damage and early OA, which, if used to treat the
patients who are likely to benefit, can reduce the number
of patients who will develop end-stage OA.
To identify novel candidate biomarkers, we used a 2-
pronged approach. The first was to use label-free quantita-
tion proteomics in a nontargeted approach with the aim of
identifying completely novel biomarkers that had not pre-
viously been associated with OA or cartilage damage/
repair. The second, targeted approach was to assess a panel
of SF and plasma proteins that we routinely test and that
have been previously associated with OA32,45 or that we
have identified as changed in response to ACI.11,12 This
method meant that any candidate proteins identified
from the proteomic analysis could be assessed in a larger
cohort to determine whether they added any predictive
value over and above other more commonly assessed OA
proteins, baseline OA severity (as deemed by Kellgren-
Lawrence score), and patient demographic characteristics,
together contributing to the development of predictive
models for patient outcome to microfracture or osteotomy
surgery. Further, particularly for the microfracture cohort,
there was a wide range of patient ages, which in itself
could account for differential abundance of some of the
measured proteins (eg, serum HA19); therefore, this statis-
tical approach could account for collinearity between
parameters, such as between age and serum HA.
One of the limitations of our study is that only a small
number of samples were used in the proteomic analysis.
This is because we wanted to select patients who demon-
strated the worst and best clinical responses to either sur-
gery, as determined by change in Lysholm scores between
preoperative and 12-month postoperative scores. Further-
more, the number of samples that could be included in these
preliminary investigations was limited to those that (1) had
sufficient volumes of SF, (2) were not too diluted (through
the lavage procedure used to collect SF at our center32) so
as to be loaded onto ProteoMiner beads for dynamic range
compression, and (3) did not have any blood staining, as
this has been demonstrated to alter the detection of SF
Figure 1. Assessment of differential abundance/activity of candidate predictive markers in responders (n = 8) compared with non-
responders (n = 11) to microfracture surgery. Concentrations (mean 6 SEM) of (A) hyaluronic acid (responders, 14.7 6 4.2 mgmL-1;
nonresponders, 19.6 6 2.6 mgmL-1; P = .52), (B) 14-3-3 protein theta (YWHAQ) (responders, 0 6 0 ngmL-1; nonresponders, 2.5 6
1.3 ngmL-1; P = .18), and (C) lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1) (responders, 13.4 6 9.2 ngmL-1; non-
responders, 5.2 6 1.5 ngmL-1; P = .918) in the synovial fluid were not different (Mann-Whitney) between responders and nonre-
sponders to microfracture surgery. (D) Enzyme activity of A disintegrin and metalloproteinase with thrombospondin motifs 4
(ADAMTS-4) was not significantly different between responders (8.8 6 8.8 ngmL-1) and nonresponders (11.5 6 5.0 ngmL-1) to
microfracture surgery (Mann-Whitney; P = .76). (E) Plasma hyaluronan (HA) concentration was not different between microfracture
responders (5.7 6 3.8 ngmL-1) and nonresponders (3.0 6 1.3 ngmL-1) (Mann-Whitney; P . .99).
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proteins.44 Therefore, it is important that these results not be
overinterpreted. We did not undertake any bioinformatic
pathway or network analyses on these proteomic findings
because of the low number of samples and again to avoid
overinterpretation of the results. In addition, the markers
identified in this preliminary proteomic study will need to
be validated in larger independent osteotomy and microfrac-
ture cohorts.
One of the proteins identified in the proteomic analyses
was 14-3-3 protein theta (YWHAQ). This protein was of par-
ticular interest for the prediction of microfracture outcome
because it was undetectable (via LC-MS/MS or ELISA) in
the SF of individuals who responded well to this procedure.
The LC-MS/MS analysis also highlighted this protein as
being detected in only the nonresponders to osteotomy.
However, 2 of the 4 samples used for proteomic analyses
demonstrated detectable concentrations of YWHAQ when
assessed with ELISA. This may be attributable to the sensi-
tivity of the ELISA, or perhaps this protein’s detection was
masked because of other more abundant proteins in the pro-
teomic analysis. We measured YWHAQ in the larger osteot-
omy patient cohort (n = 13), and this protein was not found
to have predictive value between responders and nonres-
ponders to osteotomy. Therefore, we focused on the potential
of this protein as a predictive marker for microfracture out-
come. YWHAQ concentration was a significant variable in
the linear regression model of microfracture outcome, indi-
cating that with increasing preoperative concentrations of
YWHAQ, postoperative Lysholm score decreases. When
the sample was divided into responders and nonresponders
to microfracture, based on an MCID of 10 Lysholm points,
there was no statistical difference in concentration between
the response cohorts. It is notable that in the full cohort of
microfracture patients (n = 19) assessed, representing
a more diverse range of clinical response compared with
those assessed in the proteomic analyses, none of the SF
samples of the responders had detectable levels of YWHAQ,
whereas 55% of nonresponders had detectable concentra-
tions. Therefore, there is value in testing this candidate bio-
marker protein in a larger cohort of individuals treated with
microfracture. YWHAQ is a member of the 14-3-3 protein
family, which has a wide range of functions, largely related
to signal transduction pathways.15 The role of this specific
isoform is not clear, particularly in relation to its function
in OA or cartilage tissue damage or repair. However, it
has been identified in several other relevant proteomic stud-
ies that assessed (1) the membrane proteins of equine artic-
ular chondrocytes23; (2) the secretome of cultured
chondrocytes29; (3) the SF of patients with either rheuma-
toid arthritis or OA2; and (4) the SF of rabbits subjected to
ACL transection compared with sham injury.21 Together,
these data suggest that this protein may be secreted from
chondrocytes into the SF, but how changes in the abun-
dance of this protein within the SF relate to OA disease
severity or progression requires further investigation.
In this study, we have started to develop clinical predic-
tion models for microfracture and osteotomy by performing
multiple regression analyses. Specifically, we generated a lin-
ear regression model that can correlate baseline SF HA, SF
YWHAQ, SF ADAMTS-4, SF LYVE-1, and plasma HA con-
centrations along with patient smoker status and sex with
Lysholm score at 12 months after treatment with microfrac-
ture. Moreover, although a weak correlation, a GLM with
elastic net penalization was also generated for microfracture
outcome; this again highlighted SF HA concentration, SF
ADAMTS-4 activity, and baseline Lysholm score as predic-
tors of postmicrofracture Lysholm score. Furthermore, we
generated a generalized linear regression model with elastic
net penalization that highlighted the activity of ADAMTS-4
enzyme in SF alongside patient smoker status and age as
promising predictors of osteotomy outcome. These markers
and prediction models need to be assessed in larger, indepen-
dent cohorts to confirm their clinical utility.
Both regression models of microfracture outcome high-
lighted that lower preoperative SF concentrations of HA
are predictive of higher postoperative Lysholm score and,
hence, better knee function and less pain after treatment
with microfracture. HA is a nonsulfated glycosaminoglycan
that forms an important component of articular cartilage
and the synovial membrane, and is highly concentrated in
the SF.3 Altered concentrations of HA within the SF have
long been considered a marker of degenerative joint dis-
ease,30 and serum HA levels can predict the progression of
knee OA.37 Notably, baseline levels of HA were higher in
Figure 2. None of the responders to osteotomy surgery
demonstrated detectable enzyme activity of A disintegrin
and metalloproteinase with thrombospondin motifs 4
(ADAMTS-4); however, enzyme activity was not significantly
different between the responders (n = 8) compared with non-
responders (n = 5) (responders, 0.4 6 0 ngmL-1; nonre-
sponders, 17.9 6 7.3 ngmL-1; Mann-Whitney; P = .17).
Data are expressed as mean 6 SEM.
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individuals whose OA had progressed compared with those
with earlier stage OA.37 Hence, we suggest that in our
study, individuals who demonstrated better knee function
after microfracture may have earlier-stage OA (and lower
concentrations of HA), contributing to their clinical success
compared with others who had more progressive preopera-
tive OA changes (higher levels of HA) and poorer surgical
outcomes. The potential utility of this marker for highlight-
ing, preoperatively, which individuals have more progres-
sive OA is strengthened by the fact that although the
preoperative Kellgren-Lawrence score was included as
a variable in the statistical modeling, it did not significantly
contribute to the model prediction value. Moreover, there
was not a significant difference in the baseline Kellgren-
Lawrence scores between the microfracture responder and
nonresponder cohorts. Therefore, assessment of SF HA
could perhaps be indicative of early OA severity level that
is below the detectable level using radiography in this
cohort. The immunoassay that we used in this study (Corge-
nix) is a sandwich protein binding assay that has microwells
coated with a highly specific bovine HA–binding protein to
capture HA and uses an enzyme-conjugated version of
HA-binding protein as a secondary antibody to detect and
measure HA in the samples. Higher and lower molecular
weight HAs have different molecular properties, and both
have been assessed for therapeutic and prognostic use in
OA.5,48 Therefore, in future studies to investigate the poten-
tial of HA as a candidate predictive biomarker of microfrac-
ture outcome, it would be of interest to assess the
contribution of each molecular weight variant of HA and
the biological role this protein plays.
The regression models of osteotomy and microfracture
outcome indicate that lower activity level of ADAMTS-4
in the SF preoperatively is a predictor of better patient-
reported knee function after osteotomy or microfracture.
This finding is akin to our previous work that demon-
strated that the absence of detectable ADAMTS-4 in the
SF was predictive of success after ACI.45 ADAMTS-4,
also known as aggrecanase-1, is more active in the SF of
individuals with OA.20,49 This enzyme cleaves large chon-
droitin sulphate HA–binding proteoglycans, including
aggrecan, a key structure of articular cartilage.34 Loss of
aggrecan is a key driver in the progression of OA.4,35,40
Therefore, increased or detectible activity of ADAMTS-4
in SF preoperatively may indicate that the joints of these
patient have OA that has progressed to a stage where
realignment of the joint through treatment with osteotomy
or stimulation of innate repair via microfracture surgery is
insufficient to delay or halt the progression of their OA,
explaining the propensity for their treatment to fail.
Although the model indicated that ADAMTS-4 activity is
indicative of osteotomy outcome, when patients were sepa-
rated into responders and nonresponders to this surgery
based on an MCID of 10 Lysholm points, there was no sig-
nificant difference in ADAMTS-4 activity between the
response cohorts. We suggest that when patients were sep-
arated into osteotomy responder and nonresponder catego-
ries, the difference in the activity of the ADAMTS-4
enzyme was not statistically significant because of the
low numbers of patients within each arm, particularly as
none of the patients who were classified as clinical res-
ponders had detectable enzyme activity, whereas activity
levels were detectable in 3 of the 5 nonresponders. The
same situation could also have affected the HA levels
recorded. Since the initiation of this study, patients treated
with osteotomy at our center have not routinely completed
Lysholm scores preoperatively or at 12 months after sur-
gery, thereby deeming it difficult to increase the study
numbers. We accept that this is a limitation and therefore
highlight the importance of independent validation.
In summary, we have generated a linear regression model
that can be used to help predict Lysholm score after treat-
ment with microfracture surgery. This model has highlighted
a number of candidate SF and plasma biomarkers alongside
patient demographic characteristics that have the potential
to predict microfracture outcome. Further, the activity levels
of ADAMTS-4 in SF, alongside patient smoker status and
age, have the potential to predict the outcome after osteot-
omy. These protein markers and patient demographic char-
acteristics carry the possibility of identifying individuals
who are likely to demonstrate functional improvement after
these surgeries such that the most appropriate surgical inter-
ventions can be offered to these patients, preventing the bur-
den of treatment failure and the need to reoperate or provide
an additional treatment. Alternatively, further research
aimed at understanding the biological processes underlying
the altered abundance of these proteins in individuals who
respond poorly to these surgical interventions could provide
novel therapeutic targets for the personalized augmentation
of these surgeries: for example, administering aggrecanase
inhibitors coincidently alongside osteotomy surgery. These
candidate predictive biomarkers need to be further validated
in larger independent cohorts; however, this work provides
a foundation for the identification of biomarkers to predict
outcome to interventions aimed at delaying or halting the
progression of OA.
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